ACTG Presents SLIM LIVER Findings at AASLD Liver Meeting Demonstrating Improvements in Biomarkers of Cardiovascular Risk among People Living with HIV and MASLD Who Receive Semaglutide

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced data finding that treating people living with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD) with semaglutide significantly improved a variety of biomarkers of cardiovascular risk. These results from the SLIM LIVER study (also known as A5371) will be shared as a poster presentation, “Semaglutide Improves Markers of Cardiovascular Risk in People with HIV: The SLIM LIVER Study” today, Monday, November 10, at 1:00 pm ET at the 2025 AASLD Liver Meeting, taking place in Washington D.C.